CLK1/4 kinase inhibitor (Beth Israel Deaconess Medical Center/Boston Children's Hospital)

N/A

Report date: 2025/01/26 18:58:58
NME

Base Information

Drug NameCLK1/4 kinase inhibitor (Beth Israel Deaconess Medical Center/Boston Children's Hospital)
Drug Alias NameOBD-9 (Beth Israel Deaconess Medical Center/Boston Children's Hospital)OBD-9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity protein kinase CLK4 inhibitorsTRAF2 and NCK-interacting protein kinase inhibitorsDual specificity protein kinase CLK1 inhibitors
TargetsTRAF2 and NCK-interacting protein kinaseDual specificity protein kinase CLK1Dual specificity protein kinase CLK4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesBeth Israel Deaconess Medical CenterThe Children's Hospital Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A